BC Week In Review | May 20, 2013
Company News

Clavis cancer news

Clavis said it is undergoing a "significant down scaling" of its operations following the discontinued development of elacytarabine to treat acute myelogenous leukemia in April. Clavis said most of the employees will leave the company...
BC Week In Review | Apr 8, 2013
Clinical News

Elacytarabine: Development discontinued

Clavis discontinued development of elacytarabine after the open-label, international Phase III CLAVELA trial in 380 patients with relapsed or refractory AML showed that 2,000 mg/m 2/day elacytarabine given as a continuous IV infusion on days...
BioCentury | Apr 8, 2013
Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gained $0.19 (16%) to $1.38 on Monday after receiving a preliminary comment letter from FDA that the company said "outlines a pathway" by which the biotech could submit an...
BC Extra | Apr 2, 2013
Clinical News

Clavis discontinues development of elacytarabine

Clavis Pharma ASA (OSE:CLAVIS) discontinued development of elacytarabine after the compound missed the primary endpoint of improving median overall survival (OS) vs. investigator's choice of therapy in the Phase III CLAVELA trial to treat late-stage...
BioCentury | Nov 19, 2012
Product Development

Clavis counting on PK

The pivotal failure of CO-101 from Clovis Oncology Inc. and Clavis Pharma ASA led investors to hammer both stocks, as the U.S. company lost its lead program, which used Lipid Vector technology from its Norwegian...
BioCentury | Aug 29, 2011
Product Development

Clavis does an ENT around

Clavis Pharma ASA hopes its elacytarabine can provide greater efficacy than other nucleoside analogs used to treat cancer because it doesn't rely on a cellular transporter to get into the tumor cell. New Phase II...
BC Week In Review | May 18, 2009
Clinical News

Clavis preclinical data

In vitro, CP-4200 increased re-constitution of normal cell function, reduced dependency of multidrug resistance, improved cellular uptake and demonstrated a rapid onset of activity compared to Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG, Summit, N.J.). CP-4200...
Items per page:
1 - 7 of 7